Cambridge Enterprise focuses its investments on high-impact, high-growth early-stage spin-outs and start-ups emerging from the University of Cambridge and related research institutions. Their strategy involves providing early-stage equity investment and support across diverse sectors such as life sciences, physical sciences, sustainability, healthcare, and digital health, leveraging the Cambridge ecosystem to accelerate venture development.
31% of their portfolio is in Biotech & Life Sciences. Deal activity increased 800% year-over-year (9 deals in the last 12 months). Their most common stage is seed (44% of deals). Average disclosed round size is $18.3M (across 14 rounds with reported amounts).
Portfolio
16
Fund Size
$35M
Top Stage
Seed
Last 12 Mo
9
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| SSemarion | Seed | $3.8M | Mar 2026 |
 Immutrin | Series A | $87M | Mar 2026 |
| SSeprify | Series A | $13.4M | Mar 2026 |
| XxWatts | Seed | $1.6M | Feb 2026 |
| SSparxell | Series A | $5M | Feb 2026 |
 Nu Quantum | Series A | $60M | Dec 2025 |
| CCambridge Photon Technology | Series A | $1.9M | Nov 2025 |
 CamGene Therapeutics | Seed | — | Nov 2025 |
 Trismik | Pre-Seed | — | Sep 2025 |
 Echion Technologies | Series B | $35M | Jun 2024 |
| CCarbon Re | Seed | $4.8M | Nov 2022 |
| CColorifix | Series B | $22.6M | May 2022 |
 Sano Genetics | Seed | $2.5M | Jan 2021 |
| XXampla | Seed | $6.8M | Jan 2021 |
 Riverlane | Seed | $3.7M | Jun 2019 |
| AAudioTelligence | Series A | $8.5M | — |
Top Co-Investors
Last updated: 15 April 2026